Business
ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Ultomiris offers major market opportunities through its long-acting C5 inhibition, leading to significant patient convenience and compliance with fewer infusions. Rapid conversion from older therapies and expanding regulatory approvals across multiple rare diseases enhance market penetration. Its strong sales growth and expansion into neurology and nephrology further solidify its position.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Sales Forecast and Market Size Analysis - 2034" has
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Ultomiris offers major market opportunities through its long-acting C5 inhibition, leading to significant patient convenience and compliance with fewer infusions. Rapid conversion from older therapies and expanding regulatory approvals across multiple rare diseases enhance market penetration. Its strong sales growth and expansion into neurology and nephrology further solidify its position.","length":392,"tagName":"p"},{"type":"text","content":"Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.","length":171,"tagName":"p"},{"type":"text","content":"Recent phase III data showcased ULTOMIRIS's efficacy in pediatric TMA post stem cell transplantation, with an 87.2% survival rate. The "ULTOMIRIS Sales Forecast, and Market Size Analysis - 2034" report provides insightful forecasts and market positioning, coupled with competitive intelligence and regulatory landscapes.","length":334,"tagName":"p"},{"type":"text","content":"ULTOMIRIS Drug Summary","length":22,"tagName":"p"},{"type":"text","content":"ULTOMIRIS (Ravulizumab), developed by Alexion (AstraZeneca), is a monoclonal antibody that inhibits complement C5. Indicated for PNH, aHUS, NMOSD, and gMG, it enhances patient outcomes by binding to C5 to prevent cleavage into pro-inflammatory compounds, offering sustained inhibition with long dosing intervals. Though associated with a risk of serious infections, necessitating vaccination, its broader implication in treating rare diseases cements its market position.","length":471,"tagName":"p"},{"type...